Last updated on February 2018

Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers


Brief description of study

The IMPRESS trial aims to see whether the improved results can be achieved for patients with pelvic sigmoid cancers by having an MRI scan prior to surgery so that doctors can make the most appropriate treatment choice.

Everyone who agrees to take part will be randomly allocated by one of the research team to either have standard treatment for sigmoid cancer, which involves CT-imaging of chest and abdomen / pelvis before surgery, or to undergo standard treatment, plus an additional MRI scan, before surgery. The additional MRI scan will be the only difference in approach between the two arms of the trial. After all imaging is obtained, patients from both arms will be discussed by the Multidisciplinary Team as usual. An amendment to this study in 2015 allowed for patients with sigmoid cancer who receive an MRI by local indication to be entered into the trial as observational patients, and a new primary endpoint added that compares the rates of high risk features identified between CT and MRI scans for all patients.

Detailed Study Description

The primary objective of the IMPRESS Trial will be to compare the proportion of patients undergoing any radical treatment in the two arms of the study. Another primary endpoint is to measure the difference in detection of high risk patients when comparing CT and MRI for all patients.

Secondary outcomes will measure the proportion of patients who underwent neoadjuvant treatment, quality of surgery including free resection margins, perioperative morbidity and mortality, permanent defunctioning stoma rates, downstaging, quality of life at 1 year, 3 years and 5 years.

Clinical Study Identifier: NCT02222844

Contact Investigators or Research Sites near you

Start Over

Anthony Antoniou

St Mark's Hospital
Middlesex, United Kingdom
0.05miles
  Connect »